Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

Blood (2024) 144 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2024-212973

Published: 2024

Journal Articles

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

Jennifer A. Woyach, Danielle M. Brander, Boyu Hu, Kerry A. Rogers, Zulfa Omer, Deborah M. Stephens, Andrea Sitlinger, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, Kewei Shang, John C. Byrd

Blood (2024) 144 (Supplement 1): 4622.

https://doi.org/10.1182/blood-2024-205775

Published: 2024

Journal Articles

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Sarah M. Larson, Umar Farooq, Boyu Hu, Tahir Latif, Felix A. Mensah, Deepthi Kolli, Giulia Parisi, Greg P. Kaufman, Jonathan E. Benjamin, Akil Merchant

Blood (2024) 144 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2024-200697

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Nina Wagner-Johnston, Opeyemi Jegede, Stephen E Spurgeon, Kami J. Maddocks, David T Yang, Justin Romanoff, Jonas Paludo, Paolo F. Caimi, Nancy L. Bartlett, Patrick M. Reagan, Yazeed Sawalha, Marc Hoffmann, Boyu Hu, Ashraf R Aziz, Helga Marques, Lale Kosakoglu Shields, John P. Leonard, Jonathan W. Friedberg, Brad S. Kahl

Blood (2024) 144 (Supplement 1): 236.

https://doi.org/10.1182/blood-2024-194641

Published: 2024

Journal Articles

Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation

Daniel A. Ermann, Victoria A. Vardell, Allison M. Bock, Joshua J. Horns, Harsh R. Shah, Lindsey Fitzgerald, Boyu Hu, Adam S Kittai, Deborah M. Stephens

Blood (2024) 144 (Supplement 1): 1864.

https://doi.org/10.1182/blood-2024-204134

Published: 2024

Journal Articles

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 111.

https://doi.org/10.1182/blood-2024-199330

Published: 2024

Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase

Jennifer A. Woyach, Deborah M. Stephens, Danielle M Brander, Adam S Kittai, Boyu Hu, Andrea Sitlinger, Emily K Curran, Fenlai Tan, Yi Chen, Stephen P. Anthony, Yu Chen, John C. Byrd

Blood (2023) 142 (Supplement 1): 328.

https://doi.org/10.1182/blood-2023-186432

Published: 2023

Journal Articles

Prediction of Time-to-First Treatment (TTFT) in Favorable-Risk Chronic Lymphocytic Leukemia (CLL) Patients Using a Novel Stratification through Transcriptome Risk Scoring

Boyu Hu, Brian Avery, Rosalie Griffin, Julie Feusier, Ahmad Halwani, Justin Williams, Brandt Jones, Michael Madsen, Deborah M. Stephens, Nicola J Camp

Blood (2023) 142 (Supplement 1): 1913.

https://doi.org/10.1182/blood-2023-178248

Published: 2023

Journal Articles

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

Daniel A. Ermann, Victoria A. Vardell, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Boyu Hu

Blood (2023) 142 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2023-190383

Published: 2023

Journal Articles

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2023-189652

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Victoria A. Vardell, Boyu Hu, Lindsey Fitzgerald, Harsh Shah, Allison M. Bock, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 4412.

https://doi.org/10.1182/blood-2023-190719

Published: 2023

Journal Articles

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Zach Rubnitz, Victoria A. Vardell, Lindsey Fitzgerald, Allison M. Bock, Harsh Shah, Boyu Hu, Deborah M. Stephens, Daniel A. Ermann

Blood (2023) 142 (Supplement 1): 6169.

https://doi.org/10.1182/blood-2023-189285

Published: 2023

Journal Articles

Coronado CLL : A Phase Ib/II Trial of Co mbination R p-3500 and O laparib in DNA Damage Repair Pathway D eficient Relapsed/Refract o ry C hronic L ymphocytic L eukemia

Boyu Hu, Adam S Kittai, Kenneth Boucher, Tony Pomicter, Deborah M. Stephens

Blood (2023) 142 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2023-178381

Published: 2023

Journal Articles

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Blood (2022) 140 (Supplement 1): 9390–9392.

https://doi.org/10.1182/blood-2022-159001

Published: 2022

Journal Articles

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Victoria A. Vardell, Daniel A. Ermann, Harsh Shah, Lindsey A. Fitzgerald, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 1085–1086.

https://doi.org/10.1182/blood-2022-169918

Published: 2022

Journal Articles

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Daniel A. Ermann, Victoria A. Vardell, Manasa Velagapudi, Greer Burkholder, Lindsey A. Fitzgerald, Mayur Narkhede, Harsh Shah, Lauren Shea, Adam Spivak, Deborah M. Stephens, Boyu Hu, Gaurav Goyal

Blood (2022) 140 (Supplement 1): 1076–1078.

https://doi.org/10.1182/blood-2022-169930

Published: 2022

Journal Articles

Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia

Daniel A. Ermann, Victoria A. Vardell, Lindsey A. Fitzgerald, Harsh Shah, Boyu Hu, Deborah M. Stephens

Blood (2022) 140 (Supplement 1): 6668–6669.

https://doi.org/10.1182/blood-2022-170666

Published: 2022

Journal Articles

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma

Daniel A. Ermann, Victoria A. Vardell, Harsh Shah, Randa Tao, David K. Gaffney, Deborah M. Stephens, Boyu Hu

Blood (2021) 138 (Supplement 1): 49.

https://doi.org/10.1182/blood-2021-153197

Published: 2021

NARROW

Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial

LP-168 (Rocbrutinib), a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase: Updates on the Phase 1 Trial and Initial Results of the CLL Gatekeeper Mutation Cohort

First Results of IMPT-314, an Autologous Bispecific CD19/CD20 Chimeric Antigen Receptor (CAR) in Enriched Naive and Central Memory T Cells, for the Treatment of Large B Cell Lymphoma (LBCL)

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

Real-World Comparison of BCL2 Inhibitor and BTK Inhibitor Therapy in the Front-Line Treatment of CLL Including Patients with Del(17p)/TP53 Mutation

Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

Initial Results of a Phase 1 Dose Escalation Study of LP-168, a Novel Covalent and Non-Covalent Next-Generation Inhibitor of Bruton's Tyrosine Kinase

Prediction of Time-to-First Treatment (TTFT) in Favorable-Risk Chronic Lymphocytic Leukemia (CLL) Patients Using a Novel Stratification through Transcriptome Risk Scoring

Trends in Survival Outcomes for Mantle Cell Lymphoma in the Era of Novel Therapies

AHOD2131: A Randomized Phase 3 Response-Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Real World Outcomes of Black Americans with Mantle Cell Lymphoma

Survival Outcomes of Rural Patients with Mantle Cell Lymphoma

Coronado CLL : A Phase Ib/II Trial of Co mbination R p-3500 and O laparib in DNA Damage Repair Pathway D eficient Relapsed/Refract o ry C hronic L ymphocytic L eukemia

Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments

Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy

Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia

Treatment Outcomes of Consolidative Radiation in Extranodal Early-Stage Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only